Baiji Shenzhou completed the financing of 450 million yuan for three phase I clinical trials of anticancer drugs

This round of funds comes from the original angel and strategic investors as well as new investors: Hillhouse capital, the US dollar fund of CITIC Industrial Fund and a blue chip public investment fund focusing on life technology in the United States "At present, we have three anticancer drugs with the best potential of the same kind, which are undergoing phase I clinical trials Our unique transformation research platform will continue to provide new targeted anticancer drugs for many cancer patients who currently have no drugs to treat "Yan Xiaojun, senior vice president of Baiji Shenzhou, said," we are glad that these heavyweight investors can recognize the development prospect of Baiji Shenzhou This integration will be used to continue and strengthen the support for our ongoing clinical development, so that we have the opportunity to obtain clinical data faster and provide better drugs to patients in urgent need as soon as possible We expect that in 2015, we will have two or three new drug candidates in clinical practice, and we will further invest in early product line development "At present, there are three small molecule drugs for clinical development in Baiji Shenzhou Bgb-3111, a candidate drug for Btk inhibitors, entered the first phase of clinical practice in August 2014 The PARP inhibitor bgb-290 entered clinical phase I in July 2014 The second generation of B-Raf inhibitor bgb-283 entered clinical phase I in November 2013 "With its remarkable geographical advantages, unique transformation research platform and first-class life science research ability, Baiji Shenzhou provides unique investment opportunities in the rapidly growing life science field "Hillhouse capital investors commented "We are very honored to join this group of outstanding investors to become the first financing investor of Baiji Shenzhou Hillhouse capital has been focusing on innovation, and Baiji Shenzhou is a highly innovative biotechnology company, which is very consistent with our investment philosophy We are looking forward to helping Baiji move forward in the next few years "In the past few years, Baiji Shenzhou has not only proved its first-class scientific research level, but also demonstrated its excellent clinical research and development ability At the same time, it also shows extraordinary strength in tumor immune research and development "Tang Ke, vice president of CITIC Industrial Fund, said," the cooperation agreement between Baiji Shenzhou and Merck xuelanuo and the growing product line with many anti-cancer drugs with the best potential of its kind are the reasons why we are willing to invest in Baiji Shenzhou "Related report: the first patient recruited by Baiji Shenzhou to be enrolled into bgb-3111 clinical phase I trial -- a dose-up trial of wholly-owned Btk inhibitors in patients with inert B-cell cancer to detect the single drug characteristics and preliminary antitumor efficacy -- the third candidate tumor drug to promote clinical practice in 9 months [August 26, 2014 Beijing, Nov 1: Baiji Shenzhou (Beijing) Biotechnology Co., Ltd (hereinafter referred to as Baiji) announced that the first patient has been enrolled in the first phase of bgb-3111 clinical trial Bgb-3111 is a powerful and highly selective Btk oral small molecule inhibitor developed by Baiji Brunton's tyrosine kinase (Btk) is an important signal molecule in B cell receptor (BCR) pathway The abnormal activation of BCR signaling pathway is closely related to a variety of B cell types of cancer "We are very excited about the smooth start of the first human trial of bgb-3111 Based on our current preclinical results, we have reason to believe that bgb-3111 will become the best Btk inhibitor of its kind, "said Dr Yang Jianxin, senior vice president and chief director of clinical development department of Baiji "With the strong support of our experienced team of major researchers, we are confident that the trial will be carried out smoothly, with data on efficacy, pharmacokinetics and safety, and we are expected to see some antitumor efficacy later this year, with a view to advancing the trial to the next stage." The clinical phase I trial is divided into two stages, the first stage is dose increasing stage, which will be conducted in four Australian centers; the second stage is expanding stage, which will further recruit the cohort generation of patients with specific diseases who may respond to Btk inhibitors according to the determination of the maximum tolerable dose or biological related dose Baiji is expected to complete the first phase in the second quarter of 2015 and the second phase by the end of 2015 or early 2016 "It's a great honor for me to participate in the development of such an exciting new anticancer drug," said Dr Co nstantine Tam, the lead researcher of this clinical trial and director of Peter mccarram cancer center in Melbourne "Btk inhibitors have shown impressive clinical efficacy in a variety of B-cell types of malignant tumors, and the preclinical data of bgb-3111 show that it has the potential to surpass the former We hope bgb-3111 can bring us more surprises in clinical trials " "In the past nine months, our R & D plan has been greatly accelerated with the introduction of three potential drug candidates targeting different targets into clinical practice," said Baiji CEO Ou Lei Qiang "As our first wholly-owned clinical project, bgb-3111 will further test our platform for translational medicine and witness our continued achievement of remarkable clinical milestones We expect that there will be another potential preclinical candidate drug to promote clinical application in the next few months, and we also look forward to more small molecule compounds or large molecule drugs to promote clinical application next year " At present, there are two small molecular inhibitors in the clinical development stage Both drugs were jointly developed by Baiji and Merck xuelanuo in a global cooperation: bgb-283, the second-generation B-Raf inhibitor, entered the clinical phase I test in November 2013; bgb-290, the PARP inhibitor, entered the clinical phase I test in July 2014 The first clinical trial of bgb-3111 in this trial is a multicenter, non blinded and dose increasing clinical phase I trial This study focused on the safety, tolerance and pharmacokinetics of bgb-3111 Address: Zhong Guan Cun Life Science Park, Changping District, Beijing, 102206 Tel: + 86 10 5895 8000 Fax: + 86 10 5895 8088 www.beigene.com The maximum tolerable dose, drug generation, efficacy and preliminary antitumor effect were compared Based on the determination of the maximum tolerable dose or biologically relevant dose, the extended generation (cohort) of patients with specific diseases that may respond to bgb-3111 will be further recruited About Btk protein and its inhibitor, Brunton's tyrosine kinase (Btk), is an important signal molecule in B cell receptor (BCR) pathway Btk is a member of the TEC kinase family of non receptor tyrosine kinases, which is mainly expressed in various stages of B lymphocyte development The activation process of BCR pathway includes the migration of BTK to plasma membrane, the autophosphorylation of tyrosine 223 site, the subsequent activation of downstream phospholipase PLC  2 and the release of calcium ions These signal events then activate downstream signal transduction pathways, including NF -  B, and promote the expression of genes involved in cell proliferation and survival At present, many Btk inhibitors have been proved to have a long-term antitumor effect in patients with multiple B cell types About Baiji Shenzhou (Beijing) Biotechnology Co., Ltd is a Chinese biotechnology and new drug creation company located in Zhongguancun Life Science Park, Beijing It is committed to research and develop innovative anti-cancer drugs including new chemical small molecules and biological large molecules Through independent development of new drugs found in its Chinese laboratories and cooperation with pharmaceutical partners, Baiji has authorized the joint development of new drugs under development to meet the medical needs of cancer patients in China and Asia Baiji is creating a solid biomarker and bioinformatics platform to identify the subsets of cancer patients most likely to benefit from related drugs or treatment methods, and to develop more effective and safer targeted innovative drugs by studying the relationship between drug sensitivity and target molecules For more information, please visit www.beigene.com.baiji Shenzhou to recruit the first patient into bgb-290 clinical phase I trial -- PARP inhibitor dose increasing test in specific diseases to determine single drug characteristics and preliminary antitumor efficacy [July 7, 2014, Beijing] Baiji Shenzhou (Beijing) Biotechnology Co., Ltd (hereinafter referred to as Baiji) recently announced The first patient has been enrolled in bgb-290 clinical phase I trial Bgb-290 is a powerful and highly selective oral small molecule inhibitor of PARP developed by Baiji Poly adenosine diphosphate ribose polymerase (PARP) is a kind of cell ribozyme which plays a key role in eukaryotic cells It plays an important role in maintaining the integrity of chromosome structure, participating in DNA replication and transcription, maintaining genome stability and so on It is a very popular target in the field of cancer treatment in recent years Bgb-290 is the protagonist of the second global cooperative development and sales agreement signed between Baiji and Merck The agreement signed at the end of 2013 will bring bgb-290 to the market as soon as possible with Merck's expertise in global cancer drug development and commercialization Bgb-283, the second-generation B-Raf inhibitor, the protagonist of another cooperation agreement signed before, has entered the clinical phase I trial in November 2013 "We are very excited about the smooth start of the first human trial of bgb-290 We believe that bgb-290 will be a brand new or even better PARP inhibitor, "said Baiji CEO o'reiqiang "We will continue to implement our clinical plan through our strategic cooperation with Merck xuelanuo, and we will continue to accelerate the research and development of better cancer targeted treatment drugs to meet the medical needs of cancer patients that can not be met." "We are very excited to be able to participate in the first human trial of bgb-290 in person," said Dr Michael Millward, chief researcher of this clinical trial and professor of the clinical cancer treatment Committee of the University of Western Australia "We hope that bgb-290 can show more significant advantages than similar drugs, and become an important part of the treatment plan for common cancers including small cell lung cancer, gastric cancer, brain tumor, ovarian cancer and breast cancer." The first clinical trial of bgb-290 in this trial is a multicenter, non blinded and dose increasing clinical phase I trial This study focused on the safety, tolerance and pharmacokinetics of bgb-290 The key objectives of this study were to determine the maximum tolerable dose, pharmacokinetics, efficacy and preliminary antitumor effect of bgb-290 Based on the determination of the maximum tolerable dose or biologically relevant dose, the cohort of patients with specific diseases who may respond to PARP inhibitors will be further recruited PARP protein and its inhibitors play an important role in maintaining the integrity of chromosome structure, participating in DNA replication and transcription, and maintaining genome stability PARP through the ba se excision repair (BER) pathway